ProCE Banner Activity

SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy

Slideset Download
Conference Coverage
In patients with HER2+ metatstatic breast cancer after prior anti-HER2 therapy, margetuximab + chemotherapy continues to provide PFS benefit vs trastuzumab + chemotherapy with similar OS benefit in the second interim survival analysis of SOPHIA.

Released: December 20, 2019

Expiration: December 18, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen